CYP2C19 genotype and sodium channel blockers in lacosamide-treated children with epilepsy: two major determinants of trough lacosamide concentration or clinical response.

ABSTRACT:

Background

The widespread clinical use of lacosamide (LCM) has revealed significant individual differences in clinical response, with various reported influencing factors. However, it remains unclear how genetic factors related to the disposition and clinical response of LCM, as well as drug-drug interactions (DDIs), exert their influence on pediatric patients with epilepsy.

Objectives

To evaluate the impact of genetic variations and DDIs on plasma LCM concentrations and clinical response.

Design

Patients with epilepsy treated with LCM from June 2021 to March 2023 in the Children's Hospital of Nanjing Medical University were included in the analysis.

Methods

The demographic information and laboratory examination data were obtained from the hospital information

SUBMITTER: Li Y 

PROVIDER: S-EPMC11418302 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature